PPARG and benign prostatic hyperplasia: Our novel data also show that SV could ameliorate the progression of BPH from multiple pathways, including inhibition of cell proliferation, promotion of cell apoptosis and cell cycle arrest at the G0/G1 phase, and inhibition of prostate fibrosis and the EMT process through crosstalk between PPARγ and WNT/β-catenin pathways.